Asterias Biotherapeutics Inc (NYSEAMERICAN:AST)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued on Wednesday.

Other equities analysts also recently issued reports about the stock. ValuEngine raised shares of Asterias Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 29th. Zacks Investment Research raised shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research note on Wednesday, October 25th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $9.19.

Asterias Biotherapeutics (NYSEAMERICAN:AST) opened at $2.45 on Wednesday. Asterias Biotherapeutics has a 12 month low of $2.00 and a 12 month high of $5.45.

ILLEGAL ACTIVITY WARNING: “HC Wainwright Reiterates “Buy” Rating for Asterias Biotherapeutics Inc (AST)” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.